Skip to main content
Premium Trial:

Request an Annual Quote

Lexicon s Revenues, Losses Up in Q4

NEW YORK, Feb. 19 (GenomeWeb News) - Lexicon Genetics today reported increased revenues, losses, and R&D expenses for the fourth quarter of 2003.

 

Revenues for the quarter were $13.7 million, up from $10.1 million during the same period a year ago. Lexicon attributed this increase primarily to a milestone payment from Genentech.

 

The company spent $20.3 million on R&D last quarter, up from $19.2 million during the same quarter in 2002.

 

Lexicon's net loss increased to $14.9 million, or $.24 per share, from $13.9 million, or $.26 per share, during the year-ago period.

 

As of Dec. 31, Lexicon had $161 million in cash and investments, including $57.5 million in restricted cash and investments.

 

Click here for the full earnings report.

 

The Scan

And Back

The New York Times reports that missing SARS-CoV-2 genome sequences are back in a different database.

Lacks Family Hires Attorney

A lawyer for the family of Henrietta Lacks plans to seek compensation from pharmaceutical companies that have used her cancer cells in product development, the Baltimore Sun reports.

For the Unknown

The Associated Press reports that family members are calling on the US military to use new DNA analysis techniques to identify unknown sailors and Marines who were on the USS Arizona.

PLOS Papers on Congenital Heart Disease, COVID-19 Infection Host MicroRNAs, Multiple Malformation Mutations

In PLOS this week: new genes linked to congenital heart disease, microRNAs with altered expression in COVID-19, and more.